Changes of body immunity and inflammatory response in HIV/HCV co-infected patients

Dong,Yuhong; Zhi,Xiaoli; Lei,Guo

doi:10.3892/etm.2018.6938

Changes of body immunity and inflammatory response in HIV/HCV co-infected patients

Authors:
- Yuhong Dong
- Xiaoli Zhi
- Guo Lei
View Affiliations

Affiliations: Infection Department, Qingdao No. 6 People's Hospital, Qingdao, Shandong 266000, P.R. China
Published online on: November 7, 2018 https://doi.org/10.3892/etm.2018.6938
Pages: 403-407
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Changes of body immunity and inflammatory response in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients were investigated. Eighty HIV/HCV infected patients admitted to Qingdao No. 6 People's Hospital from August 2015 to December 2017 were selected and divided into two groups according to whether they were complicated with HCV infection or not (n=40 per group). The changes of the related humoral immune indexes, the related cellular immune indexes, the related indexes of hepatic function, the related indexes of inflammatory response in the two groups were compared, and the correlations of high-sensitivity C-reactive protein (hs-CRP) level with alanine aminotransferase (ALT) level, immunoglobulin G (IgG) level and cluster of differentiation 4+ (CD4+) level in the observation group were analyzed. The levels of related humoral immune indexes [immunoglobulin G (IgG), IgA and IgM levels], the related cellular immune indexes (CD4+ and CD8+) in the observation group were lower than those in the control group (P<0.05), and the CD4+/CD8+ ratio in the observation group was lower than that in the control group (P<0.05). The levels of indexes of hepatic function [ALT, aspartate aminotransferase (AST) and total bilirubin] in the observation group were significantly higher than those in the control group (P<0.05). The levels of hs-CRP, interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) in the observation group were significantly higher than those in the control group (P<0.05). There were positive correlations of hs-CRP level with ALT level and IgG level in the observation group (P<0.05). There was a negative correlation between hs-CRP level and CD4+ level in the observation group (P<0.05). The humoral and cellular immune functions of the HIV/HCV co-infected patients are significantly limited, their hepatic function is significantly impaired and the levels of inflammatory cytokines are markedly increased. The level of hs-CRP is positively correlated with hepatic function and humoral immune function and negatively correlated with cellular immune function.

View Figures

View References

1	Mínguez C, García-Deltoro M, Flores J, Galindo MJ, Montero M, Reus S, Carmena J, Masiá M, Amador C and Ortega E: on the behalf of the COINFECOVA-2 study group: Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. AIDS. 32:337–346. 2018.PubMed/NCBI
2	Collins LF, Chan A, Zheng J, Chow SC, Wilder JM, Muir AJ and Naggie S: Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Open Forum Infect Dis. 5:ofx2642017.PubMed/NCBI
3	Ahmadinejad Z, Abdiliaei Z, Mohamadi R and Rezahosseini O: Treatment related hematologic changes in a population of Iranian patients with chronic hepatitis C infection from 2009 to 2014. Iran J Public Health. 46:1386–1394. 2017.PubMed/NCBI
4	Tavitian-Exley I, Maheu-Giroux M, Platt L, Heimer R, Uusküla A, Levina O, Vickerman P and Boily MC: Differences in risk behaviours and HIV status between primary amphetamines and opioid injectors in Estonia and Russia. Int J Drug Policy. 53:96–105. 2018. View Article : Google Scholar : PubMed/NCBI
5	Kim YC, Ahn JY, Kim JM, Kim YJ, Park DW, Yoon YK, Song JY, Kim SW, Lee JS, Choi BY, et al: Human immunodeficiency virus (HIV) and hepatitis virus coinfection among HIV-infected Korean patients: The Korea HIV/AIDS cohort study. Infect Chemother. 49:268–274. 2017. View Article : Google Scholar : PubMed/NCBI
6	Shmagel KV, Korolevskaya LB, Saidakova EV, Shmagel NG, Chereshnev VA, Margolis L, Anthony D and Lederman M: HCV coinfection of the HIV-infected patients with discordant CD4⁺ T-cell response to antiretroviral therapy leads to intense systemic inflammation. Dokl Biol Sci. 477:244–247. 2017. View Article : Google Scholar : PubMed/NCBI
7	Suda G, Ogawa K, Morikawa K and Sakamoto N: Treatment of hepatitis C in special populations. J Gastroenterol. 53:591–605. 2018. View Article : Google Scholar : PubMed/NCBI
8	Charre C, Cotte L, Kramer R, Miailhes P, Godinot M, Koffi J, Scholtès C and Ramière C: Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men. PLoS One. 13:e01903402018. View Article : Google Scholar : PubMed/NCBI
9	Ramamurthy M, Sankar S, Kannangai R, Nandagopal B and Sridharan G: Application of viromics: A new approach to the understanding of viral infections in humans. Virusdisease. 28:349–359. 2017. View Article : Google Scholar : PubMed/NCBI
10	Benhammou V, Tubiana R, Matheron S, Sellier P, Mandelbrot L, Chenadec JL, Marel E, Khoshnood B and Warszawski J: ANRS CO1/CO11-EPF French Perinatal Cohort study group: HBV or HCV coinfection in HIV-1-infected pregnant women in France: Prevalence and pregnancy outcomes. J Acquir Immune Defic Syndr. 77:439–450. 2018. View Article : Google Scholar : PubMed/NCBI
11	Mohsenizadeh M, Mollaei HR and Ghaziizadeh M: Seroepidemiological study of hepatitis B, C and HIV among blood donors in Kerman. Asian Pac J Cancer Prev. 18:3267–3272. 2017.PubMed/NCBI
12	Köse Ş, Ödemiş I, Çelik D, Tatar Gireniz B, Akbulut I and Çiftdoğan DY: Hepatitis A, B, C and HIV seroprevalence among Syrian refugee children admitted to outpatient clinics. Infez Med. 25:339–343. 2017.PubMed/NCBI
13	Raj A, Mittal G and Bahadur H: Factors affecting the serological testing of cadaveric donor cornea. Indian J Ophthalmol. 66:61–65. 2018. View Article : Google Scholar : PubMed/NCBI
14	Husseinzadeh H, Chiasakul T, Gimotty PA, Pukenas B, Wolf R, Kelty M, Chiang E, Fogarty PF and Cuker A: Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B. Haemophilia. 24:1271–277. 2018. View Article : Google Scholar
15	Fard Najafi S, Schietroma I, Scheri Corano G, Giustini N, Serafino S, Cavallari EN, Pinacchio C, De Girolamo G, Ceccarelli G, Scagnolari C, et al: Direct-acting antiviral therapy enhances total CD4⁺ and CD8⁺ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clin Res Hepatol Gastroenterol. 401:302–362. 2017.
16	Sumbu BMM, Longo-Mbenza B, Ahuka-Mundeke S, Muwonga JM, Mvumbi-Lelo G, Maphana HM, Kayembe Nzongola-Nkasu D and Kalumbu FM: Association between the viruses of the acquired immunodeficiency syndrome and the hepatitis C virus among young blood donors in Kinshasa: Retrospective analysis of 10 years. Transfus Clin Biol. 25:26–34. 2018.(In French). View Article : Google Scholar : PubMed/NCBI
17	Notari S, Tempestilli M, Fabbri G, Libertone R, Antinori A, Ammassari A and Agrati C: UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 1073:183–190. 2018. View Article : Google Scholar : PubMed/NCBI
18	Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negron J, Garcia-Broncano P, Marchetti G, Genebat M, Leal M, et al: Pegylated IFN-α-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients. Clin Infect Dis. 20:93–96. 2017.
19	D'Aleo F, Ceccarelli M, Rullo Venanzi E, Facciolà A, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Berretta M, et al: Hepatitis C-related hepatocellular carcinoma: Diagnostic and therapeutic management in HIV-patients. Eur Rev Med Pharmacol Sci. 21:5859–5867. 2017.PubMed/NCBI
20	Rial-Crestelo D, Rodríguez-Cola M, González-Gasca FJ, Geijo-Martínez P, Belinchón-Moya O, Martínez-Alfaro E, Mateos-Rodríguez F, Barberá JR, Yzusqui M, Casallo S, et al: Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection. A multicenter cohort study. Rev Esp Enferm Dig. 110:35–43. 2018.PubMed/NCBI